Fig. 1From: Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysisMean change in percentage forced vital capacity (FVC) at baseline and 6 months in the mycophenolate mofetil (MMF) and cyclophosphamide (CYC) groupsBack to article page